ocrelizumab

Kimberly H Markowitz1, Neha V Safi1, Iliana Pliska-Bloch1

  • 1Department of Neurology, Weill Cornell Medicine, New York, New York, USA.

概括

在多发性硬化症 (MS) 患者中,ocrelizumab 治疗降低了偏磁边缘病变 (PRL) 的铁含量. 这表明B细胞疗法可能会减少这些慢性活跃MS病变中的与铁相关的炎症.